Header Forschung


The Department of Pathology headed by Prof. Dr. med. Gustavo B. Baretton is one of the higher volume academic institutions for pathology in Germany. The yearly case load amounts to about 60.000 cases, including 3.000 cytologies, 3.000 molecular analyses and second opinions in gastrointestinal pathology.

A dedicated team of 10 pathologists, 8 residents and 35 technicians provides the whole spectrum of diagnostic approaches modern pathology has to offer. Our medical staff is involved in tumor boards, supports clinical studies, e.g. of the Early Clinical Train Unit (ECTU) by providing molecular or immunohistochemical tests and the tissue bank by archiving fresh frozen tumor and normal tissue for future research.

The Tumor- and Normal Tissue Bank is headed by the Director of  the  Department of Pathology and serves researchers with quality assured fresh frozen and formalin fixed paraffin-embedded tissues. The Department of Pathology also serves as the central laboratory for the SPECTAcolor initiative of the European Organization for Research and Treatment of Cancer (EORTC) through which patients with advanced colorectal cancer will gain access to innovative targeted clinical trials.

Our translational research is aimed at the identification and validation of diagnostic, prognostic and predictive biomarkers that can be detected in tumor tissue; our research foci are gastrointestinal, urological and gynecological malignancies. One recent project of a DKTK collaboration project targeted the molecular definition of tumor heterogeneity in colorectal cancer, other projects investigate the tumor microenvironment in colorectal cancer, biomarkers in immune therapy and the role of long non-coding RNAs as potential biomarkers for prostate cancer (RIBOLUTION).

Together with our colleagues from the Department of Clinical Genetics we established the Core Unit for Molecular Tumor Diagnostics (CMTD) as a research infrastructure which already serves clinical researchers with molecular characterization of sporadic and hereditary tumors based on next generation sequencing (NSG) techniques, bioinformatic analyses pipelines and interpretation of the results by experienced molecular pathologists and human geneticists. 

Members of the Department are currently setting up a Core Unit for MALDI-TOF analyses as another interesting tool for cancer research at the NCT Dresden.


Juratli TA, Prilop I, Saalfeld FC, Herold S, Meinhardt M, Wenzel C, Zeugner S, Aust DE, Barker FG 2nd, Cahill DP, Brastianos PK, Santagata S, Schackert G, Pinzer T (2021). Sporadic multiple meningiomas harbor distinct driver mutations.
Acta Neuropathol Commun. 9(1): 8
IF: 6.270


Borkowetz A, Froehner M, Rauner M, Conrad S, Erdmann K, Mayr T, Datta K, Hofbauer LC, Baretton GB, Wirth M, Fuessel S, Toma M, Muders MH (2020). Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
Int J Cancer. 146(9): 2619-2627
IF 5.145

Dreyer SB, Pinese M, Jamieson NB, Scarlett CJ, Colvin EK, Pajic M, Johns AL, Humphris JL, Wu J, Cowley MJ, Chou A, Nagrial AM, Chantrill L, Chin VT, Jones MD, Moran-Jones K, Carter CR, Dickson EJ, Samra JS, Merrett ND, Gill AJ, Kench JG, Duthie F, Miller DK, Cooke S, Aust D, Knösel T, Rümmele P, Grützmann R, Pilarsky C, Nguyen NQ, Musgrove EA, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative; Glasgow Precision Oncology Laboratory (2020). Precision oncology in surgery: patient selection for operable pancreatic cancer.
Ann Surg. 272(2):366-376
IF 10.130

Erb HHH, Sparwasser P, Diehl T, Hemmerlein-Thomas M, Tsaur I, Jüngel E, Sommer U, Baretton GB, Haferkamp A, Neisius A, Thomas C (2020). AR-V7 protein expression in circulating tumour cells is not predictive of treatment response in mCRPC.
Urol Int. 104(3-4): 253-262
IF 1.698

Friedrich M, Wiedemann K, Reiche K, Puppel SH, Pfeifer G, Zipfel I, Binder S, Köhl U, Müller GA, Engeland K, Aigner A, Füssel S, Fröhner M, Peitzsch C, Dubrovska A, Rade M, Christ S, Schreiber S, Hackermüller J, Lehmann J, Toma MI, Muders MH, Sommer U, Baretton GB, Wirth M, Horn F (2020). The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer.
Cancers (Basel). 12(5): 1122
IF 6.126

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M (2020). ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Pharmacogenomics J. 2020 Jun 16. doi: 10.1038/s41397-020-0174-1. Online ahead of print.
IF 2.910

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M (2020). Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Pharmacogenomics J. [online ahead of print]
IF 2.910

Hempel S, Oehme F, Müssle B, Aust DE, Distler M, Saeger HD, Weitz J, Welsch T (2020). Prognostic impact of para-aortic lymph node metastases in non-pancreatic periampullary cancer.
World J Surg Oncol. 18(1):16
IF 2.234

Hoberück S, Sommer U, Grey A, Hölscher T, Baretton GB, Kotzerke J (2020). Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT.
Clin Nucl Med. [Online ahead of print].
IF 6.622

Jöhrens K, von Wasielewski R, Kreipe HH, Forberger A, Jurmeister P, Dietel M, Stenzinger A, Fischer J (2020). Quality assurance in diagnostic in situ hybridization-experience of QuIP
[Article in German]
Pathologe. 41(6):614-620
IF 0.617

Jurmeister P, von Laffert M, Jöhrens K, Jurmeister P (2020). Dissecting the spatial heterogeneity of different immune cell subsets in non-small cell lung cancer.
Pathol Res Pract 216(5): 152904
IF 2.050

Kreuz M, Otto DJ, Fuessel S, Blumert C, Bertram C, Bartsch S, Loeffler D, Puppel SH, Rade M, Buschmann T, Christ S, Erdmann K, Friedrich M, Froehner M, Muders MH, Schreiber S, Specht M, Toma MI, Benigni F, Freschi M, Gandaglia G, Briganti A, Baretton GB, Loeffler M, Hackermüller J, Reiche K, Wirth M, Horn F (2020). ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer.
Eur Urol. 78(3): 452-459
IF 18.728

Lamping M, Benary M, Leyvraz S, Messerschmidt C, Blanc E, Kessler T, Schütte M, Lenze D, Jöhrens K, Burock S, Klinghammer K, Ochsenreither S, Sers C, Schäfer R, Tinhofer I, Beule D, Klauschen F, Yaspo ML, Keilholz U, Rieke DT (2020). Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
Eur J Cancer. 127: 41-51
IF 7.275

Lazzerini L, Jöhrens K, Sehouli J, Cichon G (2020). Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
Arch Gynecol Obstet. 302(5):1255-1262
IF 2.283

Meneceur S, Linge A, Meinhardt M, Hering S, Löck S, Bütof R, Krex D, Schackert G, Temme A, Baumann M, Krause M, von Neubeck C (2020). Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.
Cancers (Basel). 12(4):871
IF 6.126

Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing EJ, Hasselblatt M, Koch A, Schüller U, von Deimling A, Sahm F, Sill M, Riemenschneider MJ, Dohmen H, Monoranu CM, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Brück W, Filipski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavc I, Gerber NU, Grotzer M, Benesch M, Schlegel PG, Deinlein F, von Bueren AO, Friedrich C, Juhnke BO, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann RD, Kool M, Rutkowski S (2020). Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
J Clin Oncol. 38(18):2028-2040
IF 32.956

Noske A, Ammann JU, Wagner DC, Denkert C, Lebeau A, Sinn P, Kreipe HH, Sommer U, Baretton G, Steiger K, Kiechle M, Hieke-Schulz S, Flores M, Roth W, Weichert W (2020). A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays for scoring in triple-negative breast cancer.
Histopathology. 2020 Sep 16. doi: 10.1111/his.14254. Online ahead of print
IF 3.626

Pötzsch M, Berg E, Hummel M, Stein U, von Winterfeld M, Jöhrens K, Rau B, Daum S, Treese C (2020). Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.
Oncoimmunology. 9(1):1824632
IF 5.869

Rose M, Maurer A, Wirtz J, Bleilevens A, Waldmann T, Wenz M, Eyll M, Geelvink M, Gereitzig M, Rüchel N, Denecke B, Eltze E, Herrmann E, Toma M, Horst D, Grimm T, Denzinger S, Ecke T, Vögeli TA, Knuechel R, Maurer J, Gaisa NT (2020). EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Oncogene. 39(44):6856-6870
IF 7.971

Schmidt S, Linge A, Grosser M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; German Cancer Consortium Radiation Oncology Group (2020). Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
J Mol Diagn. 22(6): 801-810
IF 5.553

Seifert AM, Eymer A, Heiduk M, Wehner R, Tunger A, von Renesse J, Decker R, Aust DE, Welsch T, Reissfelder C, Weitz J, Schmitz M, Seifert L (2020). PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer.
Cancers (Basel). 12(10):E2756
IF 6.126

Seifert AM, List J, Heiduk M, Decker R, von Renesse J, Meinecke AC, Aust DE, Welsch T, Weitz J, Seifert L (2020). Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma.
J Cancer Res Clin Oncol. Online ahead of print
IF 3.656

Seifert AM, Reiche C, Heiduk M, Tannert A, Meinecke AC, Baier S, von Renesse J, Kahlert C, Distler M, Welsch T, Reissfelder C, Aust DE, Miller G, Weitz J, Seifert L (2020). Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Oncogene. 39(15): 3102-3113
IF 7.971

Hempel S, Oehme F, Müssle B, Aust DE, Distler M, Saeger HD, Weitz J, Welsch T.Hempel S (2020). Prognostic impact of para-aortic lymph node metastases in non-pancreatic periampullary cancer.
World J Surg Oncol. 18(1): 16
IF 1.963

Simon AG, Esser LK, Ellinger J, Branchi V, Tolkach Y, Müller S, Ritter M, Kristiansen G, Muders MH, Mayr T, Toma MI (2020). Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
J Cancer Res Clin Oncol. 146(9):2255-2265
IF 3.656

Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Göppinger S, Schwamborn K, Hieke-Schulz S, Harlow G, Flores M, Wullich B, Wirth M, Roth W, Knüchel R, Weichert W, Baretton G, Hartmann A (2020). Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Clin Genitourin Cancer. 18(5): e629-e642
IF 2.695

Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, Siebolts U, Hummel M, Herold S, Andreas J, Zoche M, Tögel L, Rempel E, Maas J, Merino D, Stewart M, Zaoui K, Schlesner M, Glimm H, Fröhling S, Allen J, Horst D, Baretton G, Wickenhauser C, Tiemann M, Evert M, Moch H, Kirchner T, Büttner R, Schirmacher P, Jung A, Haller F, Weichert W, Dietel M (2020). Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
J Thorac Oncol. 15(7): 1177-1189
IF 13.357

Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middeke JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M,  Zoephel K (2020). The prevalence of extramedullary acute myeloid leukemia detected by 18 FDG-PET/CT: final results from the prospective PETAML trial
Haematologica 105(6):1552-1558
IF 7.116

Uckermann O, Galli R, Mark G, Meinhardt M, Koch E, Schackert G, Steiner G, Kirsch M (2020). Label-free multiphoton imaging allows brain tumor recognition based on texture analysis-a study of 382 tumor patients.
Neurooncol Adv. 2(1):vdaa035

Wallace PW, Conrad C, Brückmann S, Pang Y, Caleiras E, Murakami M, Korpershoek E, Zhuang Z, Rapizzi E, Kroiss M, Gudziol V, J L M Timmers H, Mannelli M, Pietzsch J, Beuschlein F, Pacak K, Robledo M, Klink B, Peitzsch M, Gill AJ, Tischler AS, de Krijger RR, Papathomas T, Aust D, Eisenhofer G, Richter S (2020). Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
J Pathol. (online ahead of print)
IF 6.021

Wang Y, Hinz S, Uckermann O, Hönscheid P, von Schönfels W, Burmeister G, Hendricks A, Ackerman JM, Baretton GB, Hampe J, Brosch M, Schafmayer C, Shevchenko A, Zeissig S, Wang Y, et al. (2020). Shotgun lipidomics-based characterization of the landscape of lipid metabolism in colorectal cancer.
Biochim Biophys Acta Mol Cell Biol Lipids. 1865(3): 158579
IF 4.519

Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD (2020). The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Gynecol Oncol. 20: Online ahead of print
IF 4.623


Apolle R, Brückner S, Frosch S, Rehm M, Thiele J, Valentini C, Lohaus F, Babatz J, Aust DE, Hampe J, Troost EGC (2019). Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
Radiother Oncol. 133:28-34
IF 5.252

Badr M, Jöhrens K, Allgäuer M, Boxberg M, Weichert W, Tinhofer I, Denkert C, Schirmacher P, Stenzinger A, Budczies J (2019). Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.
Cancer Immunol Immunother. 68(9):1443-1454
IF 4.900

Baretton G, Kreipe HH, Schirmacher P, Gaiser T, Hofheinz R, Berghäuser KH, Koch W, Künzel C, Morris S, Rüschoff J; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group. (2019). HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
Virchows Arch. 474(5):551:560
IF 2.868

Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton G, Froehner M, Zastrow S, Wirth MP (2019). Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy.
Urol Int. 102(1): 20-26
IF 1.401

Boxberg M, Bollwein C, Jöhrens K, Kuhn PH, Haller B, Steiger K, Wolff KD, Kolk A, Jesinghaus M, Weichert W (2018). Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance.
J Clin Pathol 72(4):285-294
IF 2.346

Casadonte R, Kriegsmann M, Perren A, Baretton G, Deininger SO, Kriegsmann K, Welsch T, Pilarsky C, Kriegsmann J (2019). Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.
Proteomics Clin Appl. 13(1):e1800046
IF 2.324

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y (2019) .Tumor vessel normalization, immuno-stimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF.
Cancer Immunol Res. 7(12):1910-1927
IF 8.619

Dreyer SB, Pinese M, Jamieson NB, Scarlett CJ, Colvin EK, Pajic M, Johns AL, Humphris JL, Wu J, Cowley MJ, Chou A, Nagrial AM, Chantrill L, Chin VT, Jones MD, Moran-Jones K, Carter CR, Dickson EJ, Samra JS, Merrett ND, Gill AJ, Kench JG, Duthie F, Miller DK, Cooke S, Aust D, Knösel T, Rümmele P, Grützmann R, Pilarsky C, Nguyen NQ, Musgrove EA, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative; Glasgow Precision Oncology Laboratory (2019). Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer.
Ann Surg. 2018 [epub ahead of print]
IF 9.476

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Budach V, Tinhofer I; DKTK-ROG (2019). Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eur J Cancer.116:67-76
IF 6.680

Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, Afinowicz L, Yu KH, Grützmann R, Aust D, Gimotty PA, Pollard KS, Hruban RH, Goggins MG, Pilarsky C, Park Y, Pappin DJ, Hollingsworth MA, Tuveson DA (2019). The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.
Science. 2019 364(6446):1156-1162
IF 41.063

Froehner M, Koch R, Farahzadi S, Heberling U, Borkowetz A, Twelker L, Baretton GB, Wirth MP, Thomas C (2019). Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy.
Urol Int. 103(4):427-432
IF 1.401

Gieldon L, William D, Hackmann K, Jahn W, Jahn A, Wagner J, Rump A, Bechmann N, Nölting S, Knösel T, Gudziol V, Constantinescu G, Masjkur J, Beuschlein F, Timmers HJ, Canu L, Pacak K, Robledo M, Aust D, Schröck E, Eisenhofer G, Richter S, Klink B (2019). Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches.
Cancers (Basel).11(6). pii: E809
IF 6.162

Hartmann S, Goncharova O, Portyanko A, Sabattini E, Meinel J, Küppers R, Agostinelli C, Pileri SA, Hansmann ML (2019). CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
Mod Pathol. 32(1):37-47
IF 6.365

Hennig A, Wolf L, Jahnke B, Polster H, Seidlitz T, Werner K, Aust DE, Hampe J, Distler M, Weitz J, Stange DE, Welsch T (2019). CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids.
Stem Cells Int. 2019:1024614
IF 3.902

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, Von Der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I (2019). Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.
Oncoimmunology. 8(8):1614858
IF 5.333

Jin S, Lee WC, Aust D, Pilarsky C, Cordes N (2019). β8 Integrin Mediates Pancreatic Cancer Cell Radiochemoresistance.
Mol Cancer Res. 17(10):2126-2138
IF 4.484

Jöhrens K, Lazzerini L, Barinoff J, Sehouli J, Cichon G.
Mesothelin as a target for cervical cancer therapy
Arch Gynecol Obstet. 2019 Jan;299(1):211-216
IF 2.199

Jurmeister P, Bockmayr M, Treese C, Stein U, Lenze D, Jöhrens K, Friedling F, Dietel M, Klauschen F, Marsch W, Fiedler E, von Laffert M (2019). Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
J Dtsch Dermatol Ges. 17(8):800-808
IF 3.924

Linge A, Schmidt S, Lohaus F, Krenn C, Bandurska-Luque A, Platzek I, von Neubeck C, Appold S, Nowak A, Gudziol V, Buchholz F, Baretton GB, Baumann M, Löck S, Krause M (2019). Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy.
Clin Transl Radiat Oncol. 16:40-47

Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC (2019). Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Radiother Oncol. 135:43-50
IF 5.252

Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F (2019). The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
Eur J Cancer. 112:1-8
IF 6.680

Martin J, Lehmann A, Klauschen F, Hummel M, Lenze D, Grohé C, Tessmer A, Gottschalk J, Schmidt B, Pau HW, Witt C, Moegling S, Kromminga R, Jöhrens K (2019). Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 20(5):350-362
IF 4.117

Porschen R, Fischbach W, Gockel I, Hollerbach S, Hölscher A, Jansen PL, Miehlke S, Pech O, Stahl M, Thuss-Patience P, Vanhoefer U; und die Mitarbeiter der Leitlinienkommission; Collaborators (2019). S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus.
Z Gastroenterol. 57(3):336-418
IF 1.236

Rahbari M, Pecqueux M, Aust D, Stephan H, Tiebel O, Chatzigeorgiou A, Tonn T, Baenke F, Rao V, Ziegler N, Greif H, Lin K, Weitz J, Rahbari NN, Kahlert C (2019). Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes.
J Clin Med. 8(5). pii: E696
IF 5.688

Richter S, Gieldon L, Pang Y, Peitzsch M, Huynh T, Leton R, Viana B, Ercolino T, Mangelis A, Rapizzi E, Menschikowski M, Aust D, Kroiss M, Beuschlein F, Gudziol V, Timmers HJ, Lenders J, Mannelli M, Cascon A, Pacak K, Robledo M, Eisenhofer G, Klink B (2018). Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Genet Med. 21(3):705-17
IF 8.683

Röhnert A, Kuithan F, Riediger C, Schaab F (2019). Eine seltene Differenzialdiagnose zystischer Mesenterial-Tumoren.
Rofo. 191(7):655-57
IF 1.882

Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL (2019). Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI.
Strahlenther Onkol. 195(8):756-763
IF 2.717

Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W (2019). Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Virchows Arch. 475(5):599-608
IF 2.868

Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE (2019). Human gastric cancer modelling using organoids.
Gut. 68(2):207-217
IF 17.943

Seidlitz T, Chen YT, Uhlemann H, Schölch S, Kochall S, Merker SR, Klimova A, Hennig A, Schweitzer C, Pape K, Baretton GB, Welsch T, Aust DE, Weitz J, Koo BK, Stange DE (2019). Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Gastroenterology. 157(6):1599-1614
IF 19.809

Stasik S, Salomo K, Heberling U, Froehner M, Sommer U, Baretton GB, Ehninger G, Wirth MP, Thiede C, Fuessel S (2019). Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Clin Biochem. 64:60-63
IF 2.430

Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middeke JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M, Zoephel K (2019). The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial.
Haematologica. 2019 Aug 29. [Epub ahead of print]
IF 7.570

Sturm AK, Welsch T, Meissner C, Aust DE, Baretton G (2019). A case of biliary adenofibroma of the liver with malignant transformation: a morphomolecular case report and review of the literature
Surg Case Rep. 5(1):104

Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M (2019). The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.
J Clin Med. 8(10):E1534
IF 5.688

Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, Tunger A, Bogner A, Reißfelder C, Weitz J, Schäkel K, Troost EGC, Krause M, Folprecht G, Bornhäuser M, Bachmann MP, Aust D, Baretton G, Schmitz M (2019). Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer.
Front Immunol. 10:602
IF 4.716

Wang Y, Hinz S, Uckermann O, Hönscheid P, von Schönfels W, Burmeister G, Hendricks A, Ackerman JM, Baretton GB, Hampe J, Brosch M, Schafmayer C, Shevchenko A, Zeissig S (2019). Shotgun lipidomics-based characterization of the landscape of lipid metabolism in colorectal cancer.
Biochim Biophys Acta Mol Cell Biol Lipids [Epub ahead of print]
IF 4.402

Wenzel C (2019). [Intra-tumour heterogeneity in colorectal cancer].
Pathologe. 40(5):527-528
IF 0.546

Wiesmueller F, Kopke J, Aust D, Roy J, Dahl A, Pilarsky C, Grützmann R (2019). Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer.
Int J Mol Sci. 20(21). pii: E5437
IF 4.183

Wyvekens N, Rechsteiner M, Fritz C, Wagner U, Tchinda J, Wenzel C, Kuithan F, Horn LC, Moch H (2019). Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Virchows Arch. 474(5):625-631
IF 2.868

Zakrzewski F, de Back W, Weigert M, Wenke T, Zeugner S, Mantey R, Sperling C, Friedrich K, Roeder I, Aust D, Baretton G, Hönscheid P (219). Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues.
Sci Rep. 2019 Jun 3;9(1):8231. doi: 10.1038/s41598-019-44643-z.
IF 4.011

Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, Wagner J, Kast K, Wimberger P, Baretton G, Schröck E, Aust D, Klink B. (2019). Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
BMC Cancer 19(1):396
IF 2.933

Zimmermann C, Wolk S, Aust DE, Meier F, Saeger HD, Ehehalt F, Weitz J, Welsch T, Distler M (2019). The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.
Sci Rep. 9(1):12676
IF 4.011

Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton GB, Froehner M, Zastrow S, Wirth MP (2018). Evaluation of magnetic resonance imaging/ultrasound- fusion biopsy in patients with low- risk prostate cancer under active surveillance undergoing surveillance biopsy.
Urol Int 100:155-163
IF 1.508

Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton G, Froehner M, Zastrow S, Wirth MP (2018). Evaluation of transperineal magnetic resonance imaging/ultrasound- fusion biopsy compared to transrectal systematic biopsy in the prediction of tumour aggressiveness in patients with previously negative biopsy.
Urol Int 102:20-26
IF 1.508

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, Von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U (2018). DNA methylation-based reclassification of olfactory neuroblastoma.
Acta Neuropathol 136:255-271
IF 15.872 

Casadonte R, Kriegsmann M, Perren A, Baretton G, Deininger SO, Kriegsmann K, Welsch T, Pilarsky C, Kriegsmann J (2018). Development of a class prediction model to discriminate pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumor by MALDI mass spectrometry imaging.
Proteom Clin Appl:e1800046
IF 3.567 

Cordes N, Ney M, Beleites T, Aust DBaretton G, Thames H, Baumann M, Krause M, Löck S, Appold S (2018). Retrospective investigation of the prognostic value of the β1 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy.
PlosOne 13:e0209479
IF 2.766


Froehner M, Jahn S, Plodeck V, Laniado M, Wirth MP (2018). Chronically infected urachal remnant mimicking tumor with peritoneal carcinomatosis.
Urology 116:e3 - e4
IF 2.300 

Gieldon L, Masjkur JR, Richter S, Därr R, Lahera M, Aust D, Zeugner S, Rump A, Hackmann  K, Tzschach A, Januszewicz A, Prejbisz A, Eisenhofer G, Schrock E, Robledo M, Klink B (2018). Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1.
Eur J Endocrinol 178:K1 - K9
IF 4.333

Heberling U, Koch R, Hübler M, Baretton GB, Hakenberg OW, Wirth MP, Froehner M (2018). Gender and mortality after radical cystectomy: competing risk analysis.
Urol Int 101:293 – 299
IF 1.508

Henkel  J, Coleman CD, Schraplau A, Jöhrens K, Weiss TS, Jonas W, Schürmann A, Püschel GP (2018). Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model.
Sci Rep UK 8:16127
IF 4.122

Hirsch B, Endris V, Lassmann S, Weichert W, Pfarr N, Schirmacher P, Kovaleva V, Werner M, Bonzheim I, Fend F, Sperveslage J, Kaulich K, Zacher A, Reifenberger G, Köhrer K, Stepanow S, Lerke S, Mayr TAust DEBaretton G, Weidner S, Jung A, Kirchner T, Hansmann ML, Burbat L, Von Der Wall E, Dietel M, Hummel M (2018). Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
Virchows Arch 472:557 – 565
IF 2.936

Jarosch ASommer U, Bogner A, Reißfelder C, Weitz J, Krause M, Folprecht G, Baretton GBAust DE (2018). Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer.
Oncoimmunology 7:e1393133
IF 5.503

Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe  R, Hennig S, Makina M, Meinhardt M, Lautenschlaeger T, Schackert G, Krex D, Thiede C (2018). TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a pilot prospective study.
Clin Cancer Res 24:5282 – 5291
IF 10.199

Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner  D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK (2018). DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Acta Neuropathol 136:779 – 792
IF 15.872 

Kahlert C, Distler M, Aust D, Gieldon L, Weitz J, Welsch T (2018). Early stage pancreatic cancer.
CHIRURG 89:257 – 265
IF 0.669

Kohler A, Welsch T, Sturm AKBaretton GB, Reissfelder C, Weitz J, Riediger C (2018). Primary choriocarcinoma of the liver: a rare, but important differential diagnosis of liver lesions.
J Surg Case Rep 2018:rjy068

Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton GMeier F, Thiede C, Schmitz M, Platzbecker U (2018). Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.
Blood Adv 2:1187 - 1190

Langton K, Gruber M, Masjkur J, Steenblock C, Peitzsch M, Meinel J, Lenders J, Bornstein S, Eisenhofer G (2018). Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome.
Gynecol Endocrinol 34:20 – 24
IF 1.453

Linge A, Schötz U, Löck S, Lohaus F, Von Neubeck C, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M (2018). Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
Radiother Oncol 127:27 – 35
IF 4.942

Rezaei M, Cao J, Friedrich K, Kemper B, Brendel OGrosser M, Adrian M, Baretton G, Breier G, Schnittler HJ (2018). The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.
Histochem Cell Biol 149:15 – 30
IF 2.164

Richter S, Gieldon L, Pang Y, Peitzsch M, Huynh T, Leton R, Viana B, Ercolino T, Mangelis A, Rapizzi E, Menschikowski M, Aust D, Kroiss M, Beuschlein F, Gudziol V, Timmers HJ, Lenders J, Mannelli M, Cascon A, Pacak K, Robledo M, Eisenhofer G, Klink B (2018). Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Genet Med 21:705-717
IF 9.937

Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH, Batra SK, Datta K (2018). Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions.
Cancer Res 78:5600 – 5617
IF 9.130

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J (2018). Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Histopathol 72:449 – 459
Impact-Faktor: 3.267

Scheel AH, Penault-Llorca F, Hanna W, Baretton G, Middel P, Burchhardt J, Hofmann M, Jasani B, Rüschoff J (2018). Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Diagn Pathol 13:19
IF 2.396

Schleussner  N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, Von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S (2018). The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Leukemia 32:1994 – 2007
IF 10.023

Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, Von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs  SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S (2018). Development and validation of a gene signature for patients with head and neck carcinomas treated by postoperative radio(chemo)therapy.
Clin Cancer Res 24:1364 – 1374
IF 10.199

Seidlitz T, Merker SR, Rothe A, Zakrzewski F, Von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE (2018). Human gastric cancer modelling using organoids.
GUT 68(2): 207-217
IF 17.016 

Thiele S, Zimmer A, Göbel A, Rachner TD, Rother S, Fuessel S, Froehner M, Wirth MP, Muders MHBaretton GB, Jakob F, Rauner M, Hofbauer LC (2018). Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.
Oncotarget 9:27293 – 27304
IF 5.168

Uckermann O, Yao W, Juratli TA, Galli R, Leipnitz E, Meinhardt M, Koch E, Schackert G, Steiner G, Kirsch M (2018). IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy.
J Neuro Oncol 139:261 – 268
IF 3.060

Ullrich M., Liers J, Peitzsch M, Feldmann A, Bergmann R, Sommer U, Richter S, Bornstein SR, Bachmann M, Eisenhofer G, Ziegler CG, Pietzsch J (2018). Strain-specific metastatic phenotypes in pheochromocytoma allograft mice.
Endocr Relat Cancer 25:993 – 1004
IF 5.331

Welsch T, Seifert A, Müssle B, Distler M, Aust DE, Weitz J (2018). The "T" now matters:the eighth edition of the union for international cancer control classification of pancreatic adenocarcinoma.
Ann Surg 268:e36 - e37
IF 9.203


Werthmann PG, Inter P, Welsch T, Sturm AK, Grützmann R, Debus M, Sterner MG, Kienle GS (2018). Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: a case report.
Medicine 97: e13243
IF 2.028 

Zeissig S, Schmelz R, Brückner S, Aust DEBaretton GB, Hampe J (2018). Direct endoscopy and diagnosis of adenocarcinoma following metal stent-based drainage of a pancreatic cyst.
Endoscopy 50: E72 - E73
IF 6.629

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren, A, Lugli A, Toma MBaretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr  R, Hartmann A, Bertz S (2018). Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Hum Pathol 80:55 – 64
IF 3.125


Al-Gburi S, Deussen AJ, Galli R, Muders MH, Zatschler B, Neisser A, Müller B, Kopaliani I (2017). Sex-specific differences in age-dependent progression of aortic dysfunction and related cardiac remodeling in spontaneously hypertensive rats
Am J Physiol Regul Integr Comp Physiol 312(5):R835-R849

Baretton GB (2017). Gastric tumors.
Pathologe 38(2):65-66

Baretton GB, Aust DE (2017). Current biomarkers for gastric cancer
Pathologe 38(2): 93-97

Betzler AM, Kochall S, Blickensdörfer L, Garcia SA, Thepkaysone ML, Nanduri LK, Muders MH, Weitz J, Reissfelder C, Schölch S (2017). A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
J Vis Exp 125

Betzler A, Mees ST, Pump J, Schölch S, Zimmermann C, Aust DE, Weitz J, Welsch T, Distler M (2017). Clinical impact of duodenal pancreatic heterotopia - Is there a need for surgical treatment?
BMC Surg 17(1):53

Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, Herout R, Baunacke M, Laniado M, Baretton G, Radtke JP, Kesch C, Hohenfellner M, Froehner M, Schlemmer HP, Wirth M, Zastrow S (2017). Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients
BJU Int. 121(1): 53-60

Borkowetz A, Platzek I, Toma M, Renner T, Herout R, Baunacke M, Laniado M, Baretton GB, Froehner M, Zastrow S, Wirth MP (2017) Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
Urol Int. 99(2): 177-185

Brandt D, Sergon M, Abraham S, Mäbert K, Hedrich CM (2017). TCR+CD3+CD4-CD8- effector T cells in psoriasis
Clin Immunol 181: 51-59

Czink E, Kloor M, Goeppert B, Froehling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Jaeger D, Springfeld C (2017). Successful immune checkpoint blockade in a patient with advanced stage microsatellite unstable biliary tract cancer
Cold Spring Harb Mol Case Stud 3(5): a001974

Endhardt K, Märkl B, Probst A, Schaller T, Aust D (2017). Value of histomorphometric tumour thickness and smoothelin for conventional m-classification in early oesophageal adenocarcinoma
World J Gastrointest Oncol 9(11): 444-451

Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M, Vollbrecht C, Penzel R, Volckmar AL, Stenzinger A, Endris V, Jung A, Lehmann U, Zeugner S, Baretton G, Kreipe H, Schirmacher P, Kirchner T, Dietel M, Büttner R, Merkelbach-Bruse S (2017). EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
Virchows Arch. [Epub ahead of print]

Froehner M, Koch R, Propping S, Liebeheim D, Hübler M, Baretton GB, Hakenberg OW, Wirth MP (2017). Level of education and mortality after radical prostatectomy.
Asian J Androl 19(2): 173-177

Froehner M, Toma M, Zöphel K, Novotny V, Laniado M, Wirth MP (2017). PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings
Case Rep Urol 2017:1654231

Froehner M, Kuithan F, Zöphel K, Heberling U, Laniado M, Wirth MP (2017). Prostate-specific membrane antigen-targeted ligand positron emission tomography /computed tomography and immunohistochemical findings in a patient with synchronous metastatic penile and prostate cancer
Urology 101:e5-e6

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C (2017). Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Nat Med 23(1):69-78

Hauptmann S, Friedrich K, Redline R, Avril S (2017). Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.
Virchows Arch 470(2): 125-142

Hempel S, Plodeck V, Mierke F, Distler M, Aust DE, Saeger HD, Weitz J, Welsch T (2017). Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection
Sci Rep 7(1):7688

Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U (2017). Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
Leukemia [Epub ahead of print]. Letter to the editor

Herold S*, Kuhn M*, Bonin MV*, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Röllig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhäuser M, Thiede C (2017). Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient
Leukemia 31(7): 1637-1640 [*contributed equally]. Letter to the editor

Hofmann SR, Kapplusch F, Girschick HJ, Morbach H, Pablik J, Ferguson PJ, Hedrich CM (2017). Chronic recurrent multifocal osteomyelitis (CRMO): presentation, pathogenesis, and treatment
Curr Osteoporos Rep [Epub ahead of print]

Jahny E, Yang H, Liu B, Jahnke B, Lademann F, Knösel T, Rümmele P, Grützmann R, Aust DE, Pilarsky C, Denz A (2017). The G Protein-Coupled Receptor RAI3 is an independent prognostic factor for pancreatic cancer survival and regulates proliferation via STAT3 phosphorylation
PLoS One 12(1): e0170390

Jarosch A, Sommer U, Bogner A, Reißfelder C, Weitz J, Krause M, Folprecht G, Baretton GB, Aust DE (2017). Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+ /Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer
Oncoimmunology 7(2): e1393133

Kahlert C, Distler M, Aust D, Gieldon L, Weitz J, Welsch T (2017). [Early stage pancreatic cancer]
Chirurg [epub ahead of print]

Kast K, Schoffer O, Link T, Forberger A, Petzold A, Niedostatek A, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P (2017).  Trastuzumab and survival of patients with metastatic breast cancer
Arch Gynecol Obstet 296(2): 303-312

Keiler AM, Macejova D, Dietz BM, Bolton JL, Pauli GF, Chen SN, van Breemen RB, Nikolic D, Goerl F, Muders MH, Zierau O, Vollmer G (2017). Evaluation of estrogenic potency of a standardized hops extract on mammary gland biology and on MNU-induced mammary tumor growth in rats
J Steroid Biochem Mol Biol 174: 234-241

Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V*, Luther T* (2017). Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patient’s prognosis
Am J Cancer Res 7(9): 1959-1970

Kriegsmann M, Longuespée R, Wandernoth P, Mohanu C, Lisenko K, Weichert W, Warth A, Dienemann H, De Pauw E, Katzenberger T, Aust D, Baretton G, Kriegsmann J, Casadonte R (2017). Typing of colon and lung adenocarcinoma by high throughput imaging mass spectrometry
Biochim Biophys Acta1865(7): 858-864

Kunz-Schughart LA, Dubrovska A, Peitzsch C, Ewe A, Aigner A, Schellenburg S, Muders MH, Hampel S, Cirillo G, Iemma F, Tietze R, Alexiou C, Stephan H, Zarschler K, Vittorio O, Kavallaris M, Parak WJ, Mädler L, Pokhrel S (2017). Nanoparticles for radiooncology: mission, vision, challenges
Biomaterials 120: 155-184

Lachmann P, Hickmann L, Steglich A, Al-Mekhlafi M, Gerlach M, Jetschin N, Jahn S, Hamann B, Wnuk M, Madsen K, Djonov V, Chen M, Weinstein LS, Hohenstein B, Hugo CPM, Todorov VT (2017). Interference with Gsα-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial Damage
J Am Soc Nephrol 28(12):3479-3489

Langton K, Gruber M, Masjkur J, Steenblock C, Peitzsch M, Meinel J, Lenders J, Bornstein S, Eisenhofer G (2017). Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome
Gynecol Endocrinol [Epub ahead of print]

Laske J, Sergon M, Mentzel T, Beissert S, Maschke J (2017). Congenital dermatofibrosarcoma protuberans clinically mimicking a melanocytic naevus treated with serial excisions
J Eur Acad Dermatol Venereol [Epub ahead of print]. Letter to the editor

Linge A, Schötz U, Löck S, Lohaus F, Neubeck CV, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG (2017). Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
Radiother Oncol. 127(1): 27-35

Link T, Kuithan F, Ehninger A, Kuhlmann JD, Kramer M, Werner A, Gatzweiler A, Richter B, Ehninger G, Baretton G, Bachmann M, Wimberger P, Friedrich K (2017). Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.
Oncotarget 8(33): 54592-54603

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G (2017). HER2 testing in gastric cancer: results of a German expert meeting.
J Cancer Res Clin Oncol 143(5):835-841

Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F (2017). 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.
Eur J Cancer 79:41-49

Mamlouk S*, Childs LH*, Aust D*, Heim D, Melching F, Oliveira C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C (2017). DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. [*gleichber. Erstautorin]
Nat Commun 8: 14093

Müssle B, Distler M, Wolk S, Shrikhande SV, Aust DE, Arlt A, Weitz J, Hackert T, Welsch T (2017). Management of patients with pancreatic cystic lesions: A case-based survey
Pancreatology 17(3):431-437

Richter C, Herrero San Juan M, Weigmann B, Bergis D, Dauber K, Muders MH, Baretton GB, Pfeilschifter JM, Bonig H, Brenner S, Radeke HH (2017). Defective IL-23/IL-17 Axis Protects p47phox-/- Mice from Colon Cancer.
Front Immunol 8:44

Röcken C, Baretton GB, Kreipe HH, Kirchner T (2017). University Pathology in Germany
Pathologe 38(4): 324-330

Rößler S, Bader O, Stölzel F, Sommer U, Spiess B, Geibel S, Buchheidt D, Groß U, Baretton G, Jacobs E, Ostrosky-Zeichner L (2017). Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a cyp51A TR46 Y121F M172I T289A Allele
Antimicrob Agents Chemother 61(8): e00270-17

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J (2017). Interlaboratory-concordance of PD-L1 immunohisto-chemistry for non-small cell lung cancer
Histopathology 72(3): 449-459

Schellenburg S, Schulz A, Poitz DM, Muders MH (2017). Role of neuropilin-2 in the immune system
Mol Immunol 90: 239-244

Solimena M, Schulte AM, Marselli L, Ehehalt F, Richter D, Kleeberg M, Mziaut H, Knoch KP, Parnis J, Bugliani M, Siddiq A, Jörns A, Burdet F, Liechti R, Suleiman M, Margerie D, Syed F, Distler M, Grützmann R, Petretto E, Moreno-Moral A, Wegbrod C, Sönmez A, Pfriem K, Friedrich A, Meinel J, Wollheim CB, Baretton GB, Scharfmann R, Nogoceke E, Bonifacio E, Sturm D, Meyer-Puttlitz B, Boggi U, Saeger HD, Filipponi F, Lesche M, Meda P, Dahl A, Wigger L, Xenarios I, Falchi M, Thorens B, Weitz J, Bokvist K, Lenzen S, Rutter GA, Froguel P, von Bülow M, Ibberson M, Marchetti P (2017). Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes
Diabetologia 61(3): 641-657

Teske C, Schweitzer C, Palamidessi A, Aust DE, Scita G, Weitz J, Welsch T (2017). Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells
Biochem Biophys Res Commun 493(1):528-533

Uckermann O, Galli R, Leupold S, Coras R, Meinhardt M, Hallmeyer-Elgner S, Mayer T, Storch A, Schackert G, Koch E, Blümcke I, Steiner G, Kirsch M (2017). Label-free multiphoton microscopy reveals altered tissue architecture in hippocampal sclerosis
Epilepsia 58(1):e1-e5

Volk A, Plodeck V, Toma M, Saeger HD, Pistorius S (2017). Treatment of tailgut cysts by extended distal rectal segmental resection with rectoanal anastomosis
Surg Today 47(4): 457-462

Welsch T, Seifert A, Müssle B, Distler M, Aust DE, Weitz J (2017). The "T" now Matters: The Eighth Edition of the Union for International Cancer Control Classification of Pancreatic Adenocarcinoma
Ann Surg 268(2): e36-e37

Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M (2017). Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy
Eur J Nucl Med Mol Imaging 44(11): 1813-1822